Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Treating lipids in cardiovascular disease: new directions
Autore:
Wiklund, O;
Indirizzi:
Sahlgrens Univ Hosp, Dept Cardiol, SE-41345 Gothenburg, Sweden Sahlgrens Univ Hosp Gothenburg Sweden SE-41345 -41345 Gothenburg, Sweden
Titolo Testata:
EUROPEAN HEART JOURNAL SUPPLEMENTS
fascicolo: B, volume: 3, anno: 2001,
pagine: B27 - B31
SICI:
1520-765X(200105)3:B<B27:TLICDN>2.0.ZU;2-G
Fonte:
ISI
Lingua:
ENG
Soggetto:
DENSITY-LIPOPROTEIN CHOLESTEROL; CORONARY HEART-DISEASE; TO-RETENTION HYPOTHESIS; MYOCARDIAL-INFARCTION; ARTERIAL-WALL; LDL; HYPERCHOLESTEROLEMIA; SUBFRACTIONS; EFFICACY; SAFETY;
Keywords:
cardiovascular disease; low-density lipoprotein; high-density lipoprotein; statins; cerivastatin;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
26
Recensione:
Indirizzi per estratti:
Indirizzo: Wiklund, O Sahlgrens Univ Hosp, Dept Cardiol, SE-41345 Gothenburg, Sweden Sahlgrens Univ Hosp Gothenburg Sweden SE-41345 enburg, Sweden
Citazione:
O. Wiklund, "Treating lipids in cardiovascular disease: new directions", EUR H J SUP, 3(B), 2001, pp. B27-B31

Abstract

Aims To review the importance of lipid parameters beside low-density lipoprotein (LDL) levels as risk factors for cardiovascular disease, and their potential as therapeutic targets for lipid-lowering agents. Methods and Results Large numbers of studies have shown that, as well as high low-density lipoprotein (LDL) levels, low high-density lipoprotein (HDL) levels and a high LDL/HDL ratio are important cardiovascular disease riskfactors. The new generation of statins, such as cerivastatin, demonstratesgreater potency in getting more patients to their LDL-C targets, as recommended by the U.S. NCEP guidelines. Statins and also fibrates call increase HDL levels. In the VA-HIT study, for example, a 6% increase in HDL level using gemfibrozil was associated with a 22% reduction in the relative risk ofcoronary events compared with placebo. Statin treatment, by decreasing LDLand increasing HDL levels, produces strong reductions in the LDL/HDL ratio. In a cerivastatin study, the percentage of patients with LDL/HDL ratio <3(low risk of coronary heart disease) increased from 32% (baseline) to 90% after 8 weeks of therapy. The density profile of LDL particles also affectscardiovascular disease risk. Studies have shown that small dense LDL particles have atherogenic properties, and that lipid-lowering therapy can alterthe LDL density profile. The TRIGMA trial is investigating the effect of cerivastatin on LDL particle size and triglyceride levels in patients with type 2 diabetes. Conclusions Other lipid parameters, besides LDL levels, can provide new targets for lipid intervention therapy.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/01/20 alle ore 10:12:42